Preemption In Pharmaceutical Cases: 2017 In Review

Law360 (February 6, 2018, 11:10 AM EST) -- 2017 was a busy year in the evolving landscape of preemption in pharmaceutical cases. Below are a few of the preemption opinions that caught our attention.

Preemption of Warnings Claims

In Wyeth v. Levine,[1] the U.S. Supreme Court issued its landmark opinion on the preemptive scope of failure-to-warn claims in brand drug cases. The court held that absent "clear evidence" that the U.S. Food and Drug Administration would have rejected a manufacturer's label change, failure-to-warn claims against brand-name drug makers are not preempted.[2] What constitutes "clear evidence" that the FDA would have rejected a label change remains the subject of considerable...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!